Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

@article{Devonshire2012RelapseAD,
  title={Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.},
  author={Virginia A. Devonshire and Eva Kubala Havrdov{\'a} and Ernst Wilhelm Radue and P. K. O'Connor and Lixin Zhang-Auberson and Catherine Agoropoulou and Dieter Adrian H{\"a}ring and Gordon Francis and Ludwig Kappos},
  journal={The Lancet. Neurology},
  year={2012},
  volume={11 5},
  pages={420-8}
}
BACKGROUND Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in MS) study, fingolimod significantly reduced annualised relapse rates (ARRs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
51 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

Similar Papers

Loading similar papers…